TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04605614

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Copper Cu 64-DOTA-pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET
Study: NCT05514951

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood sampling
Study: NCT05216666

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lateral approach
Description: Total hip arthroplasty performed through a lateral surgical approach (Gammer)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Posterior approach
Description: Total hip arthroplasty performed through a posterior surgical approach (Moore)
Study: NCT05709132

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iPeer2Peer Program
Description: Behavioral: iPeer2Peer Support Mentorship Program is an online peer support mentorship program that has been established in multiple chronic disease populations as a self-management intervention, including chronic pain and juvenile idiopathic arthritis. The iPeer2Peer program provides modeling and reinforcement by pre-screened and trained young adult peer mentors to adolescent mentees.
Study: NCT04690439

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBMT)
Description: The MLS M6 laser from ASA will be used to apply the laser therapy.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Photobiomodulation therapy (PBMT)
Description: The MLS M6 laser from ASA will be used to apply the laser therapy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual Lymphatic drainage
Description: Patients will receive twice weekly MLT executed by trained physiotherapist

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Lymphatic drainage
Description: Patients will receive twice weekly MLT executed by trained physiotherapist
Study: NCT05382377

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KD-025
Description: Autologous genetically modified anti-NKG2DLs CAR transduced T cells
Study: NCT05063786

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: 6 mg/kg IV every 3 weeks (3-weekly schedule), or 4 mg/kg IV loading dose, followed by 2mg/kg IV weekly (weekly schedule)\*, or 600 mg SC every 3 weeks.~\* If using trastuzumab IV, a loading dose of 8 mg/kg (for the 3-weekly schedule), or 4 mg/kg (for the weekly schedule) is necessary if more than 6 weeks have passed since the previous trastuzumab dose.
Study: NCT04447053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab Injection [Benlysta]
Description: Belimumab, IV infusion, 10mg/kg on days 0, 14, 28 then every 28 days until week 48.
Study: NCT06574633

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-person therapy
Description: Participants will be referred to in-person therapy services when facilitating referral resources by a dedicated behavioral mental health specialist (BMHS).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth therapy
Description: Participants will be referred to telehealth therapy services when facilitating referral resources by a dedicated behavioral mental health specialist (BMHS).
Study: NCT05338229

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the engineer-built system, video-game based Kinect sensor
Description: The engineer-built system, video-game based Kinect sensor was developed by the researcher team.
Study: NCT05489081

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Behavior Management Toolkit
Description: The Positive Behavior Management Toolkit, or the implementation strategy resource package, is a set of resources provided to teachers in the intervention group that aims to support their use of positive behavior management practices in the classroom, particularly with students with hyperactive, inattentive, or impulsive behaviors.
Study: NCT06273969

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment (OMT)
Description: The OMT protocol is designed to target the somatic dysfunction associated with TOS. The somatic dysfunction associated with TOS include muscular hypertonicity of the anterior and middle scalene muscles, hypertonicity of the pectoralis muscles, and tension in the fascia of the supraclavicular area between the clavicle and first rib. The OMT protocol will consist of the following four techniques:~Direct Thoracic Inlet Myofascial Release (TIMFR) - Reduce tension at the thoracic inlet fascia located between the thoracic outlet and the cervical spine.~Direct Muscle Energy for the Scalene Muscles -Reduce tension within the scalene muscle group~Direct Muscle Energy for the Pectoralis Muscles - Reduce tension within the pectoralis muscle group~Supraclavicular Fascial Release - Reduce fascial tension within the supraclavicular fossa
Study: NCT05337618

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Full-band Electrocorticography
Description: Diagnosis of spreading depolarizations in continuous electrocorticography

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Treatment Algorithm
Description: Protocol for escalation and de-escalation of physiologic-targeted and pharmacologic therapies to treat and prevent spreading depolarizations
Study: NCT06295445

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: care cardio-pulmonary ultrasound
Description: Evaluation of the heart and lung conditions in shocked patients using focused cardio-pulmonary ultrasound for treatment guidance and their implication on the patient's outcome

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: treatment without any use of point of care cardio-pulmonary ultrasound scans for guidance of the management
Description: treatment without any use of point of care cardio-pulmonary ultrasound scans for guidance of the management
Study: NCT05063786

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 6 mg/kg IV every 3 weeks (3-weekly schedule), or 4 mg/kg IV loading dose, followed by 2mg/kg IV weekly (weekly schedule)\*, or 600 mg SC every 3 weeks.~\* If using trastuzumab IV, a loading dose of 8 mg/kg (for the 3-weekly schedule), or 4 mg/kg (for the weekly schedule) is necessary if more than 6 weeks have passed since the previous trastuzumab dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 6 mg/kg IV every 3 weeks (3-weekly schedule), or 4 mg/kg IV loading dose, followed by 2mg/kg IV weekly (weekly schedule)\*, or 600 mg SC every 3 weeks.~\* If using trastuzumab IV, a loading dose of 8 mg/kg (for the 3-weekly schedule), or 4 mg/kg (for the weekly schedule) is necessary if more than 6 weeks have passed since the previous trastuzumab dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: 300 mg oral once daily.
Study: NCT05718401

Intervention type: DEVICE
Intervention: NMR
Description: nuclear magnetic resonance in genomics

Intervention type: DEVICE
Intervention: NMR
Description: nuclear magnetic resonance in genomics
Study: NCT05063786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: 300 mg oral once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500 mg intramuscular every 4 weeks plus loading dose on day 15 cycle 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: Oral (60 mg/m2) or IV (25 or 30 mg/m2 per investigator preference) on days 1 and 8, every 3 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 1250 or 1000 mg/m2 (per investigator preference) twice a day (BID) oral, 2 weeks on, 1 week off, every 3 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eribulin
Description: 1.23 mg/m2 IV on days 1 and 8, every 3 weeks.
Study: NCT05558930

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iTBS stimulation
Description: standard iTBS burst pattern:3 pulses at 50-Hz repeated at a rate of 5-Hz; 20 trains of 10 bursts given with 8-s intervals. 600 pulses on both side of cerebellar with an interval of 5 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham stimulation
Description: Participants receive a sound stimulation with the same pattern with iTBS stimulation,but without magnetic field
Study: NCT05393219

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac biofeedback
Description: 6 minutes of relaxing breathing exercise coupled with heart rate variability biofeedback guided on emWave Pro software on a computer just before entering the examination circuit

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: 6 minutes of a guided video tape made for the study that inspires mindfulness like meditation associated just before entering the examination circuit.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resources mobilization
Description: 6 minutes of a guided video tape that purpose to mobilize inner resources and strength of the student just before entering the examination circuit.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: 6 minutes of standardized neutral video on general topics that generates no modification of affects just before entering the examination circuit.
Study: NCT05572476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Association of lurbinectedin and durvalumab
Description: A treatment cycles consists of 3 weeks (i.e. 21 days). Lurbinectedin will be administered by intravenous infusion on Day 1 every 3 weeks.~Durvalumab will be administered by intravenous infusion on Day 1 every 3 weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: Association of carboplatin and etoposide
Description: Treatment will be administered on a 21-days cycle basis up to a maximum of 6 cycles.~Carboplatin will be administered by intravenous infusion on Day 1 every 3 weeks.~Etoposide will be administered by intravenous infusion on Day 1-3 every 3 weeks
Study: NCT04188730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lofexidine (granules for reconstitution)
Description: All subjects will be administered one 0.36 mg dose of lofexidine granules for reconstitution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lofexidine (granules for reconstitution)
Description: All subjects will be administered one 0.36 mg dose of lofexidine granules for reconstitution.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LUCEMYRA (lofexidine) tablets
Description: All subjects will be administered one 0.36 mg dose of LUCEMYRA (lofexidine) tablets.
Study: NCT06316479

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PTMC Dermal Filler
Description: A total of 120 subjects will receive treatment with PTMC Dermal Filler. The volume of filler injected will vary depending on the severity of the nasolabial fold. Injections will be administered by the investigator at the beginning of the study, with the injection technique, plane, and volume recorded. Touch-up treatments are permitted at the 1-month follow-up visit, if necessary.
Study: NCT05175170

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision-aid
Description: The decision aid consists of domains related to human reproduction, fertility, and fertility preservation. The domains address priority learning objectives in each domain to increase knowledge on the impact of gender-affirming medical interventions on fertility and fertility preservation options.
Study: NCT06656403

Intervention type: DRUG
Group type: OTHER
Intervention: 0.1% sodium hyaluronate
Description: After baseline measurement, 0.1% sodium hyaluronate eye drops were instillation into the inferior conjunctival vault of both eyes

Intervention type: DRUG
Group type: OTHER
Intervention: 0.1% sodium hyaluronate
Description: After baseline measurement, 0.1% sodium hyaluronate eye drops were instillation into the inferior conjunctival vault of both eyes
Study: NCT06657040

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MUSIC
Description: The intervention group will receive a soundtrack through individual choice of anti-noise headphones. The music offer platform will be provided by an application developed by MusicCare (www.music.care/en/index.html) in two periods of the day (09:00 and 16:00), lasting 45 minutes each, for up to seven postoperative days or until discharge from the unit (whichever occurs first). MusicCare has been widely tested in several countries and there are a large number of publications in anesthesiology, ICU, cardiology and neurology, among other specialties, demonstrating its safety and efficacy69,70. Patients who were hospitalized for more than 48 hours, that is, who received a minimum of 4 intervention periods, will be considered as patients with effective intervention. Patients with less time will be evaluated in the form of intention to treat.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: MUSIC
Description: The intervention group will receive a soundtrack through individual choice of anti-noise headphones. The music offer platform will be provided by an application developed by MusicCare (www.music.care/en/index.html) in two periods of the day (09:00 and 16:00), lasting 45 minutes each, for up to seven postoperative days or until discharge from the unit (whichever occurs first). MusicCare has been widely tested in several countries and there are a large number of publications in anesthesiology, ICU, cardiology and neurology, among other specialties, demonstrating its safety and efficacy69,70. Patients who were hospitalized for more than 48 hours, that is, who received a minimum of 4 intervention periods, will be considered as patients with effective intervention. Patients with less time will be evaluated in the form of intention to treat.
Study: NCT03849326

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Quality of life Depression Physical pain Social provisions Quality of sleep

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Quality of life Depression Physical pain Social provisions Quality of sleep

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood test
Description: complete blood count and cytokine concentration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood test
Description: complete blood count and cytokine concentration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maximal effort test
Description: The maximal effort test with VO2max recordings will be assessed during the first visit to the laboratory.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maximal effort test
Description: The maximal effort test with VO2max recordings will be assessed during the first visit to the laboratory.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: actigraphy
Description: assessment of sleep quality

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: actigraphy
Description: assessment of sleep quality

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular evaluation
Description: * The maximum isometric force produced by the knee extensors will be measured on the ergometer~* the intensity of muscular electrical activity recorded by surface electromyography~* Peripheral nerve stimulation~* Transcranial magnetic stimulation~* Magnetic resonance imaging (optional)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular evaluation
Description: * The maximum isometric force produced by the knee extensors will be measured on the ergometer~* the intensity of muscular electrical activity recorded by surface electromyography~* Peripheral nerve stimulation~* Transcranial magnetic stimulation~* Magnetic resonance imaging (optional)
Study: NCT05121415

Intervention type: GENETIC
Intervention: SNP analysis of the DNA
Description: SNP analysis of the DNA obtained from peripheral blood sample

Intervention type: GENETIC
Intervention: SNP analysis of the DNA
Description: SNP analysis of the DNA obtained from peripheral blood sample
Study: NCT06314087

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo + conventional treatment including radiotherapy
Description: Placebo + conventional treatment including radiotherapy

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Radiation: Radiation Therapy；Biological: Personalized tumor peptide vaccine
Description: The peptide vaccine treatment will take 5 months as a treatment course until the treatment suspension event as stipulated in the plan occurred.
Study: NCT06119958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWC202313
Description: Experimental Drug 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWC202314
Description: Experimental Drug 2
Study: NCT06005324

Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel
Description: Given as part of induction chemotherapy.

Intervention type: DRUG
Group type: OTHER
Intervention: Carboplatin
Description: Given as part of induction chemotherapy.

Intervention type: DRUG
Group type: OTHER
Intervention: Cetuximab
Description: Given as part of induction chemotherapy.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard Dose Radiation
Description: Radiation given once daily for 5 days for 7 weeks as part of CRT regimen.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low Dose Radiation
Description: Radiation given once daily for 5 days for 6.5 weeks as part of CRT regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given as part of CRT regimen (7 weekly doses). Investigator will choose the appropriate chemotherapy backbone to be given during CRT.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given as part of CRT regimen (7 weekly doses). Investigator will choose the appropriate chemotherapy backbone to be given during CRT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TFHX Regimen
Description: Chemotherapy with paclitaxel, fluorouracil (5FU), and hydroxyurea given in combination with radiation therapy. Investigator will choose the appropriate chemotherapy backbone to be given during CRT.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TFHX Regimen
Description: Chemotherapy with paclitaxel, fluorouracil (5FU), and hydroxyurea given in combination with radiation therapy. Investigator will choose the appropriate chemotherapy backbone to be given during CRT.
Study: NCT03029637

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RBBs with no or minimal preparation of their abutment teeth
Description: Placement of resin bonded bridges on teeth with no or minimal cutting of their supporting teeth

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RBBs with routine tooth preparation of their abutment teeth
Description: Placement of resin bonded bridges on teeth after routine cutting of their supporting teeth
Study: NCT05908565

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Demographic Matching
Description: At randomization, students will be randomized to a Latinx or non-Latinx coach and will be informed whether or not their coach identifies as Latinx. Although we are not recruiting coaches or matching coaches with participants based on gender, gender identity or lived experience with mental health problems, we will collect these data from coaches in order to do conduct secondary exploratory analyses examining these variables as predictors or moderators of outcome.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervision Intensity
Description: Coaches will be assigned to either standard supervision or reduced supervision, with equal distribution across Latinx vs non-Latinx. Coaches assigned to standard supervision will receive weekly supervision by a licensed provider consistent with the procedures outlined in the Data and Safety Monitoring Plan for the Signature Project. Coaches assigned to reduced supervision will attend weekly group supervision, but their session recordings or live sessions will not be reviewed by licensed supervisors or advanced peers and they will not receive personalized feedback about how they are performing in their sessions. Students will not be informed which supervision condition they have been assigned to in order to maintain high treatment expectancies. Of note, this design prohibits the coach and supervisors from being blind to participant condition.
Study: NCT04690699

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lerapolturev
Description: Lerapolturev administered via intravesical instillation once

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lerapolturev
Description: Lerapolturev administered via intravesical instillation once

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5% DDM
Description: 5% DDM and saline washes
Study: NCT05976256

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Kinesio taping
Description: Kinesio tape is a thin, elastic tape that applies pressure to the skin (because of the elasticity of the tape), reducing pain by reducing nociceptive stimulation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sham tape (leukotape classic)
Description: leuko tape classic is used in this study to explore the possible placebo effect of kinesiotape

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment
Description: standard treatment is the treatment with oral analgesics and a sling (if shoulder injury)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: standard treatment
Description: standard treatment is the treatment with oral analgesics and a sling (if shoulder injury)
Study: NCT06193473

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group: Group to which the clinical pharmacist makes recommendations
Description: The drugs administered to patients within 24-48 hours after hospitalization were recorded. A detailed medication review will be conducted by the clinical pharmacist during the participants' hospitalization.As a result of a comprehensive evaluation, recommendations were made to doctors regarding drug-related problems and were recorded.